A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach

Francesco Lanza; Francesco Saraceni; Annalisa Pezzi; Massimo Martino; Alberto Bosi; Nicola Cascavilla; Pellegrino Musto; Eliana Zuffa; Monica Tani; Claudia Cellini; Daniele Laszlo; Francesca Bonifazi

doi:10.1002/ajh.24817

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach

Francesco Lanza, Francesco Saraceni, Annalisa Pezzi, Massimo Martino, Alberto Bosi, Nicola Cascavilla, Pellegrino Musto, Eliana Zuffa, Monica Tani, Claudia Cellini, Daniele Laszlo, Francesca Bonifazi

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	E557-E559
Journal	American Journal of Hematology
Volume	92
Issue number	9
DOIs	https://doi.org/10.1002/ajh.24817
Publication status	Published - Sep 2017

Keywords

Biosimilar Pharmaceuticals/administration & dosage
Blood Cell Count
Filgrastim/administration & dosage
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds/administration & dosage
Humans
Lymphoma, Non-Hodgkin/blood
Multiple Myeloma/blood
Propensity Score
Retrospective Studies

Cite this

Lanza, F., Saraceni, F., Pezzi, A., Martino, M., Bosi, A., Cascavilla, N., ... Bonifazi, F. (2017). A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. American Journal of Hematology, 92(9), E557-E559. https://doi.org/10.1002/ajh.24817

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma : a propensity-score weighted multicenter approach. / Lanza, Francesco; Saraceni, Francesco; Pezzi, Annalisa; Martino, Massimo; Bosi, Alberto; Cascavilla, Nicola; Musto, Pellegrino; Zuffa, Eliana; Tani, Monica; Cellini, Claudia; Laszlo, Daniele; Bonifazi, Francesca.

In: American Journal of Hematology, Vol. 92, No. 9, 09.2017, p. E557-E559.

Research output: Contribution to journal › Article

Lanza, F, Saraceni, F, Pezzi, A, Martino, M, Bosi, A, Cascavilla, N, Musto, P, Zuffa, E, Tani, M, Cellini, C, Laszlo, D & Bonifazi, F 2017, 'A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach', American Journal of Hematology, vol. 92, no. 9, pp. E557-E559. https://doi.org/10.1002/ajh.24817

Lanza, Francesco ; Saraceni, Francesco ; Pezzi, Annalisa ; Martino, Massimo ; Bosi, Alberto ; Cascavilla, Nicola ; Musto, Pellegrino ; Zuffa, Eliana ; Tani, Monica ; Cellini, Claudia ; Laszlo, Daniele ; Bonifazi, Francesca. / A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma : a propensity-score weighted multicenter approach. In: American Journal of Hematology. 2017 ; Vol. 92, No. 9. pp. E557-E559.

@article{5d85fde21c60479e8a9f138bd2862fda,

title = "A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach",

keywords = "Biosimilar Pharmaceuticals/administration & dosage, Blood Cell Count, Filgrastim/administration & dosage, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds/administration & dosage, Humans, Lymphoma, Non-Hodgkin/blood, Multiple Myeloma/blood, Propensity Score, Retrospective Studies",

author = "Francesco Lanza and Francesco Saraceni and Annalisa Pezzi and Massimo Martino and Alberto Bosi and Nicola Cascavilla and Pellegrino Musto and Eliana Zuffa and Monica Tani and Claudia Cellini and Daniele Laszlo and Francesca Bonifazi",

year = "2017",

month = "9",

doi = "10.1002/ajh.24817",

language = "English",

volume = "92",

pages = "E557--E559",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma

T2 - a propensity-score weighted multicenter approach

AU - Lanza, Francesco

AU - Saraceni, Francesco

AU - Pezzi, Annalisa

AU - Martino, Massimo

AU - Bosi, Alberto

AU - Cascavilla, Nicola

AU - Musto, Pellegrino

AU - Zuffa, Eliana

AU - Tani, Monica

AU - Cellini, Claudia

AU - Laszlo, Daniele

AU - Bonifazi, Francesca

PY - 2017/9

Y1 - 2017/9

KW - Biosimilar Pharmaceuticals/administration & dosage

KW - Blood Cell Count

KW - Filgrastim/administration & dosage

KW - Hematopoietic Stem Cell Mobilization

KW - Heterocyclic Compounds/administration & dosage

KW - Humans

KW - Lymphoma, Non-Hodgkin/blood

KW - Multiple Myeloma/blood

KW - Propensity Score

KW - Retrospective Studies

U2 - 10.1002/ajh.24817

DO - 10.1002/ajh.24817

M3 - Article

C2 - 28612372

VL - 92

SP - E557-E559

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -

Access to Document

10.1002/ajh.24817